biocon & ms.

shaw - Presentation Transcript

1. THE BIOCON STORY 2.

o o o o o o o
3.

Indias Leading Biotech enterprise Established in 1978 Focus on development of Biopharmaceuticals 1 st in Asia & 16 th in world in terms of revenue and market capitalization Syngene, Indias first biotech custom research company in drug discovery First company to manufacture human insulin using a Pichia expression system Indias first billion dollar biotech company

Products include: Biopharmaceuticals Anti-Diabetic Agents Anti-Hypertensive Agents Anti-Inflammatory Agents Antioxidants Cardiovascular Agents Digestive Aid Enzymes Haemostatic Agents Hepatoprotective Agents Immunosuppressants Nutraceuticals Enzymes Amylases Cellulases Esterases Glucanases Hemicellulases/Xylanases Oxidases Pectinases Proteases Tannase 4.

o o o o o o

Born on 23 March 1953 in Bangalore B.Sc Zoology from Bangalore university 1973 Master brewer from Ballarat University in Melbourne 1975 Trainee brewer in Carlton & United Beverages in 1975-77 First Indian woman brew master Joined Biocon biochemical Ltd. Ireland in 1978

5.

Dr. Kiran M. Shaw In 1978 founded Biocon India The journey begins

o o o o o o o 

Collaborated with irish firm Biocon international Kiran owned 70% and Auchinloss (biocon int.) owned 30% of equity Started Biocon India from her garage. Initial Capital Rs/- 10,000. Started extracting enzyme (papain) from papaya & isinglass (fish moss) Export to irish firm Novel product patenting e.g: Enzyme to clarify tea

6.

o o o

Early Hurdles: Financing regular operations Approached financial institutions, but turned down, coz:

   o

Biotechnology is a new word No assets for company Woman entrepreneur is a rare word

Recruiting staff

 o

Only well qualified people

In 1985,

 
7.

Employees join communist labor union Kiran automated the whole plant

o o o

Early years Started with loan from KSFC Proactive scientific interest

  o o

Building up germplasm of tropical m.o (Biodiversity) Doing research on the metabolites of these m.o

Did not start antibiotic prod. (no commodity production in early stage) HUMAN CAPITAL / PEOPLE (5 th P of marketing strategy)

       
8.

Exceptionally well qualified individuals Above average salary Elegant & Refined working environment Constant company of proff. (real good people with real good people) Calling first names in company Very much structured and purposive manner ESOP Attrition rate less than 1% (turnover only due to higher studies)

o o

Breakthrough: Switched from uninspiring low technology to high end technology

o o o o o

New technology replaced tray based conventional culture Plafractor Bioreactor: all m.o processes in a computerized closed system Acted as a technology bridge (platform technology) Enabled biocon to cross from ind. Enzymes to biopharmaceuticals Started R&D in immunosuppressants (reduce immune rejections)

Plafractor 9. o Strategies

o o o o o o o o o o

No commodity production in beginning due to lack of infrastructure Diversification rather than expansion Formed Helix (antibiotic prod.) Formed Syngene, Clinigene (R&D in fermentation) Biocon Quest (BQ) to produce these products in mass Marketing strategy Enzymes produced & sold as industrial intermediaries Customer (staying with buyers processing line helping them obtain desired result from the enzyme) Created an image of a reliable company able to give highly competent technical products & support Also custom based products at any level

10. MILESTONES 11. 2004,Post IPO, became the richest Indian woman (U.S $ 480 million) I978, started Biocon India Ltd. in collaboration with Biocon Int. 1990s, Unilever collaboration & Plafractor technology 1998, Biocon became a separate identity by buying Unilever share. 1996, got into Biopharmaceuticals & statins 12.

o o o o o o o o

Noteworthy Decisions Emphasizing on significant product & applications even when company is tiny Contract R&D firm to outsource research Systematic collection & cataloguing of tropical m.o for future (biodiversity pool) ESOP for retaining employees Launch of Insurgen , first branded formulation (Recombinant Human Insulin) Managing IPR Core emphasis right from the beginning

o o o

Major IP management came with invention of Plafractor Joined PCT which gave a lot of protection and time to explore countries. Got into Human insulin production by attaining a process patent

 

Produced Human Insulin through Pichia Yeast (biodiversity pool helped) Mutual beneficial partnership with Nobex for oral insulin delivery

13. SUCCESS MANTRA MS. SHAW

o o o o

Determination Willingness to take risk Talented team Spirit of Adventure

14. Future

o o

ORAL INSULIN has the potential to be Indias first proprietary biotech blockbuster drug by 2010

  o

Pre-clinical studies to evaluate safety and efficacy in animal models has commenced. Biocon has initiated discussions with Pharma majors for licensing Oral Insulin for global markets.

ORAL PEPTIDE product for cardio vascular disease

 o

Joined with U.S based Nobex Corp.

ANTICANCER DRUGS

  o

Plan to build Asias largest Antibody facility Joined with CIMAB (renowned Cuban research Inst.)

VACCINES

  
15. 16. 17. Brand

Psoriasis Rheumatoid Arthritis 3 Cancer vaccines

o o

Dynamic Helix or Dynalix Multiple associations like DNA helix, molecules, interlocking Bs (Biocon & Biotech )

o o

Slanting shows companys forward and upward vision About Branding:

 

To convey innovation , quality, reliability, distinctiveness & int. outlook Pale blue packaging was chosen to stand out among std. white packages

18. Recognition: Padma Bhushan (2005) The Economic Times Business Woman of the Year Award (2004) Ernst & Young Entrepreneur of the Year Award in Healthcare & Life Sciences (2002) Padma Shri (1989) Outstanding Young Person Award by Jaycees (1987) Rotary award for the Best Model Employer (1983) Outstanding Contribution Award (AWAKE) (1983) Gold for Best Woman Entrepreneur , Institute of Marketing Management (1982) Positions Held: Chairperson and Mission Leader of CII's National Task Force on Biotechnology Member, Board of Science Foundation, Ireland Member, Board of Governors, IIM Bangalore Chairperson, Karnataka's Vision Group on Biotechnology Vice-President, Association of Women Entrepreneurs of Karnataka (AWAKE) 19. "If I can build a company like Biocon, anyone can The first step was to dream however big or small. If you have a vision, no matter how big or small, a plan, no matter if it is imperfect, but if there is passion and conviction for it, success is inevitable." - Kiran Mazumdar Shaw, Managing Director, Biocon India Limited.